Achieve Life Sciences is trading 5.3% down at $6.00, extending a decline triggered by an FDA Complete Response Letter (CRL) for cytisinicline and significant capital-raising activities.
- The CRL issued on June 20, 2026, was reportedly tied to manufacturing and labeling requirements rather than concerns regarding the drug's clinical efficacy or safety.
- Shares continue to face pressure from an up to $354 million private placement and a previous underwritten offering, compounded by broader risk-off sentiment across the biotech sector.